FDA Clearance Tracker · P040047-S046
Coaptite Injectable Implant
Last checked: Nov 20, 2026Latest source record: Mar 28, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Mar 28, 2018
Approved
Time to decision
167 days
Received Oct 12, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P040047-S046
- Device name
- Coaptite Injectable Implant
- Applicant
- Merz North America, Inc.
- Applicant location
- Franksville, WI
- Received
- Oct 12, 2017
- Decided
- Mar 28, 2018
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P040047
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
Approval of the alternate manufacturing facility located at 13900 W. Grandview Parkway Sturtevant.
Source documents
Other decisions for Merz North America, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250016 · Decided Jul 9, 2026 · 387 days after receipt
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.